Key result
Rare damaging MAP3K7 variants are linked to ~22-fold higher odds of dilated cardiomyopathy.
Why the study?
Many patients with dilated cardiomyopathy (DCM) lack a molecular diagnosis. Although MAP3K7 variants are a known cause of syndromic cardiospondylocarpofacial syndrome, it remained unknown whether MAP3K7 variants can cause primary or isolated DCM without overt syndromic features.
Do loss-of-function genetic variants in MAP3K7 cause apparently isolated dilated cardiomyopathy across the lifespan?
Case-Control (n=1,449)
Yes
Do loss-of-function genetic variants in MAP3K7 cause apparently isolated dilated cardiomyopathy across the lifespan?
Loss-of-function variants in MAP3K7 are a novel monogenic cause of apparently isolated dilated cardiomyopathy in both children and adults, supporting the inclusion of MAP3K7 in routine clinical genetic diagnostic panels for DCM.
Answers are grounded in this paper and cite their sources.
MAP3K7 variants may warrant inclusion in DCM panels; leaves open prevalence, penetrance, and causality in larger cohorts.
Background and Aims Dilated cardiomyopathy (DCM) is a genetically heterogeneous cause of heart failure and sudden cardiac death. Many patients remain without a molecular diagnosis. MAP3K7 encodes TAK1, a serine/threonine kinase important for cardiac homeostasis . MAP3K7 variants are an established cause of syndromic disease, including cardiospondylocarpofacial syndrome (CSCF), in which DCM has been occasionally reported. Here, we demonstrate that MAP3K7 variants can cause apparently isolated DCM, expanding the phenotypic spectrum of MAP3K7 -related disorders. Methods We integrated four lines of genetic evidence: de novo variation, common variant association, familial segregation, and rare variant enrichment, alongside functional characterisation. Results In 117 paediatric cardiomyopathy trios from the 100,000 Genomes Project, two probands harboured rare de novo MAP3K7 missense variants, significantly more than expected (Bonferroni-adjusted p=0.036). Independent GWAS implicated MAP3K7 as a susceptibility locus for adult DCM. Across global DCM cohorts, we identified families harbouring rare MAP3K7 variants, including one with segregation in nine affected relatives (p.(Tyr125Cys), estimated LOD = 2.7). Rare damaging non-truncating variants were enriched in DCM versus INTERVAL (OR 22, P=0.007) and gnomAD controls (OR 14, P=6.2×10⁻⁴), while truncating variants were associated with DCM in Genomics England and increased left ventricular volumes in UK Biobank. DCM-associated variants reduced TAK1 kinase activity, supporting a loss-of-function mechanism consistent with CSCF-associated alleles. Conclusion Multiple independent lines of evidence establish an association between MAP3K7 loss of function variants and DCM. Several affected individuals lacked overt syndromic features, demonstrating that MAP3K7 -related disease may present as apparently isolated DCM across the lifespan and supporting inclusion of MAP3K7 in DCM diagnostic pipelines. GRAPHICAL ABSTRACT Key Question: Do MAP3K7 variants cause isolated dilated cardiomyopathy? MAP3K7 variants are known to cause rare syndromic disease, including cardiospondylocarpofacial syndrome (CSCF). Some patients with CSCF develop dilated cardiomyopathy (DCM), however we do not know whether MAP3K7 variants cause primary or isolated DCM without overt syndromic disease. Key Finding We present multiple orthogonal data sources supporting an association between MAP3K7 loss-of-function variants and DCM. The collective evidence for this gene-disease association encompasses paediatric trio de novo discovery, GWAS, familial segregation, rare variant case-control analysis and variant categorisation in vitro . Strong segregation evidence was obtained for p.(Tyr125Cys), with nine clinically affected genotype-positive individuals in one pedigree (estimated LOD score 2.7). Further, p.(Cys266del) was observed in three affected individuals in one family and a de novo paediatric case. Take-Home Message Loss-of-function variants in MAP3K7 are associated with DCM and several affected individuals lack overt syndromic features. MAP3K7 -related disease may present as apparently isolated DCM across the lifespan. These findings support the incorporation of MAP3K7 testing into DCM diagnostic pipelines.
No takes yet. Share an insight, caveat, or question.
Josephs et al. (2026) conducted a case-control in Dilated cardiomyopathy (DCM) (n=1,449). Rare damaging non-truncating variants in MAP3K7 vs. Population controls without rare damaging MAP3K7 variants (INTERVAL study and gnomAD v4.1) was evaluated on Enrichment of rare damaging non-truncating MAP3K7 variants in dilated cardiomyopathy cases versus INTERVAL controls (OR 22, p=0.007). Rare damaging non-truncating MAP3K7 variants were significantly enriched in dilated cardiomyopathy cases versus INTERVAL (OR 22, P=0.007) and gnomAD controls (OR 14, P=6.2×10⁻⁴).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: